RegeneRx Biopharmaceuticals, Inc.
RGRX · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0% | -0% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -1,589.3% | -0.8% | 2.4% | -0.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,006.3% | -2,037.5% | -1,907.2% | -2,845.1% |
| EPS Diluted | -0.003 | -0.003 | -0.003 | -0.004 |
| % Growth | 0% | -3.8% | 31.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |